Vaccines against SARS-CoV-2 are safe to administer in patients with antibodies to pegaspargase.
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
03
06
2022
accepted:
30
06
2022
pubmed:
16
7
2022
medline:
1
2
2023
entrez:
15
7
2022
Statut:
ppublish
Résumé
Allergic reactions to pegaspargase during ALL therapy are typically due to antibodies against polyethylene glycol (PEG), which is also used as a stabilizing agent in mRNA-based SARS-CoV-2 vaccines. To evaluate the safety of these vaccines in patients with anti-pegaspargase antibodies. We retrospectively reviewed the records of patients treated for ALL who had received SARS-CoV-2 vaccinations. All patients had antibodies against pegaspargase assayed during ALL therapy prospectively and in response to clinical allergies. Symptoms of intolerance to vaccination were gathered retrospectively from chart abstraction. SARS-CoV-2 vaccination was well tolerated in all 78 patients with prior exposure to pegaspargase as part of their leukemia therapy. No reactions were observed in the 54 patients without a history of anti-pegaspargase antibodies or in 19 patients with antibodies who received mRNA vaccination. 1 patient who received the polysorbate containing Janssen vaccine experienced mild symptoms after vaccination not meeting the criteria of clinical allergy which spontaneously resolved within 25 minutes. SARS-CoV-2 vaccination is safe in this population.
Identifiants
pubmed: 35837830
doi: 10.1002/cam4.5011
pmc: PMC9349948
doi:
Substances chimiques
Antibodies
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Polyethylene Glycols
3WJQ0SDW1A
RNA, Messenger
0
Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1552-1555Subventions
Organisme : NCI NIH HHS
ID : CA21765
Pays : United States
Organisme : NCI NIH HHS
ID : CA250418
Pays : United States
Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Services CfDCaPUSDoHH. Interim clinical considerations for use of COVID-19 vaccines. CDC. 2022;2022. Accessed July 7, 2022. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html
Risma KA, Edwards KM, Hummell DS, et al. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol. 2021;147(6):2075-2082 e2072.
Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy. 2021;51(6):861-863.
Kloos RQH, Pieters R, Jumelet FMV, de Groot-Kruseman HA, van den Bos C, van der Sluis IM. Individualized asparaginase dosing in childhood acute lymphoblastic leukemia. J Clin Oncol. 2020;38(7):715-724.
Jeha S, Pei D, Choi J, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total therapy study 16. J Clin Oncol. 2019;37(35):3377-3391.
Vrooman LM, Blonquist TM, Stevenson KE, et al. Efficacy and toxicity of Pegaspargase and Calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496-3505.
Liu Y, Smith CA, Panetta JC, et al. Antibodies predict Pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37(23):2051-2061.
Greenhawt M, Abrams EM, Shaker M, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: A systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021;9(10):3546-3567.
Mukkada S, Bhakta N, Chantada GL, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol. 2021;22(10):1416-1426.
Moreira DC, Millen GC, Sands S, Kearns PR, Hawkins DS. The care of children with cancer during the COVID-19 pandemic. Am Soc Clin Oncol Educ Book. 2021;41:1-10.
Meena JP, Kumar Gupta A, Tanwar P, Ram Jat K, Mohan Pandey R, Seth R. Clinical presentations and outcomes of children with cancer and COVID-19: a systematic review. Pediatr Blood Cancer. 2021;68(6):e29005.
Koo G, Anvari S, Friedman DL, et al. mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase. J Allergy Clin Immunol Pract. 2022;10(1):322-325.
Rush C, Faulk KE, Bradley ZK, Turner A, Krumins M, Greenhawt M. The safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: a single institution experience. J Allergy Clin Immunol Pract. 2022;10(2):630-632.
Mark C, Gupta S, Punnett A, et al. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer. 2021;68(11):e29295.
Ieven T, Van Weyenbergh T, Vandebotermet M, Devolder D, Breynaert C, Schrijvers R. Tolerability of polysorbate 80-containing COVID-19 vaccines in confirmed polyethylene glycol-allergic patients. J Allergy Clin Immunol Pract. 2021;9(12):4470-4472 e4471.
Stone CA Jr, Liu Y, Relling MV, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7(5):1533-1540 e1538.